Latest News

Explore our latest corporate news, events and press releases.

Larka Advises Partners Group On Its Acquisition Of FairJourney Biologics

3 July 2024 - Larka is pleased to announce it performed the Commercial Due Diligence for Partners Group—supporting its acquisition of FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO).

Merger & Acquisition

Larka Advises Motion Equity On Its Acquisition Of Banook

3 November 2023 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Motion Equity Partners—supporting its acquisition of Banook, a leading French Central Service Provider.

Merger & Acquisition

Larka Performs 4 Sourcing Processes for Global BioPharma Clients.

23 October 2023 - Leveraging Lensource®, Larka enabled the identification and selection of CRO, CDMO and CMO partners for 4 major Biotech & Pharma clients, including...

Tech Ops & Outsourcing

CMO Sourcing Process for Juvisé Pharmaceuticals

15 May 2023 - Juvisé Pharmaceuticals leveraged Larka’s Lensource® solution for the identification, assessment and selection of a Contract Manufacturing Organisation (CMO) partner to supply one of its commercial products.

Tech Ops & Outsourcing

Larka Advises Biose Industrie, Acquired by L-GAM & the French State

17 March 2023 - Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Biose Industrie—a world-leading Contract Development and Manufacturing Organisation (CDMO)—acquired by L-GAM & the French State.

Merger & Acquisition

Larka Advises Apax Partners On Its Acquisition Of Porsolt

8 March 2023 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Apax Partners, supporting its acquisition of Porsolt, a leading French Contract Research Organization (CRO).

Merger & Acquisition

Larka Supports Albumedix' Sale Process, Acquired by Sartorius

26 October 2022 - Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Albumedix – a leading recombinant albumin-based solution provider based in Nottingham, UK – acquired by the Sartorius Group.

Merger & Acquisition

Larka Advises Keensight on CRO Axxam Acquisition

1 September 2022 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence provider to support Keensight Capital on its acquisition of a majority stake in Axxam, a global-leading Contract Research Organization (CRO) based in Italy.

Merger & Acquisition

Larka Advises Cathay on its Investment in CRO Transcure

31 August 2022 - Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France.

Merger & Acquisition

Larka Advises Merieux Equity Partners on its investment in Janvier Labs

26 July 2022 - Larka provides Merieux Equity Partners with a Commercial Due Diligence to support its investment in French BioPharma company Janvier Labs.

Merger & Acquisition

Larka Advises Elyan on CRO Oncodesign Acquisition Process

11 July 2022 - Larka provides Elyan Partners with a Commercial Due Diligence to support the acquisition of CRO services Business Unit of Oncodesign, a leading French BioPharma company.

Merger & Acquisition

Larka Advises Gimv on CDMO BioConnection Investment Deal

24 May 2022 - Larka provides Gimv with a Technical Due Diligence and Operational Due Diligence to support its investment in leading Dutch bio-CDMO BioConnection.

Merger & Acquisition

Interview with: Yana Marmann

25 April 2022 - Fresh out of college and hired amid the COVID-19 pandemic, Yana saw in Larka an opportunity to shape a career within the BioPharma industry while evolving in a fast-paced and exciting environment.

Our People

Vendor Due Diligence for Afinum and SHS | evitria

27 July 2021 - Larka is very pleased to announce that it’s M&A Unit performed the Vendor Commercial Due-Diligence to support Afinum’s exit process of evitria, a global leading service provider specialized in transient antibody expression.

Merger & Acquisition

Commercial Due Diligence for Keensight Capital | Symeres

7 June 2021 - Larka is very proud to announce that it performed the Commercial-Due-Diligence for Keensight Capital on its acquisition of Symeres.

Merger & Acquisition

Commercial Due Diligence for Clean Biologics & Archimed | Biodextris

11 May 2021 - Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed - on their acquisition of Biodextris.

Merger & Acquisition

New Office

9 August 2020 - As a result of a strong and continued growth in recent years, we are delighted to announce the opening of our new office in Nice.

Corporate News

Integrated Due Diligence for Cathay Capital | Biose

20 July 2020 - Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Cathay Capital.

Merger & Acquisition

Integrated Due Diligence for Keensight Capital | 3P Biopharmaceuticals

30 July 2019 - Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital.

Merger & Acquisition